vs
Idexx Laboratories(IDXX)とロク(ROKU)の財務データ比較。上の社名をクリックして会社を切り替えられます
ロクの直近四半期売上が大きい($1.2B vs $1.1B、Idexx Laboratoriesの約1.1倍)。Idexx Laboratoriesの純利益率が高く(22.8% vs -2.2%、差は25.0%)。Idexx Laboratoriesの前年同期比売上増加率が高い(14.3% vs -18.3%)。Idexx Laboratoriesの直近四半期フリーキャッシュフローが多い($326.3M vs $298.4M)。過去8四半期でロクの売上複合成長率が高い(13.6% vs 6.4%)
IDEXXラボラトリーズは1983年設立の米国多国籍企業で、伴侶動物獣医療、家畜・家禽、水質検査、乳製品分野向けの製品・サービスの開発・製造・流通を手がけています。本社はメイン州ウェストブルックにあり、EMEA地域の拠点はオランダのホーフドルプに置かれています。
ロクは2002年にアンソニー・ウッドが創設した米国のストリーミング技術企業です。デジタルメディアプレーヤーやテレビの製造、ストリーミングサービスの配信、プラットフォーム広告事業を手がけ、2024年時点で1億4500万人のユーザーに到達する米国市場のリーダーであり、豪州、カナダ、欧州、中南米でも事業を展開しています。
IDXX vs ROKU — 直接比較
損益計算書 — Q4 FY2025 vs Q1 FY2026
| 指標 | ||
|---|---|---|
| 売上 | $1.1B | $1.2B |
| 純利益 | $248.2M | $-27.4M |
| 粗利率 | 60.3% | 35.6% |
| 営業利益率 | 28.9% | 59.7% |
| 純利益率 | 22.8% | -2.2% |
| 売上前年比 | 14.3% | -18.3% |
| 純利益前年比 | 14.8% | -361.0% |
| EPS(希薄化後) | $3.09 | $0.57 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.1B | $1.4B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $1.1B | $1.1B | ||
| Q1 25 | $998.4M | $1.0B | ||
| Q4 24 | $954.3M | $1.2B | ||
| Q3 24 | $975.5M | $1.1B | ||
| Q2 24 | $1.0B | $968.2M |
| Q1 26 | — | $-27.4M | ||
| Q4 25 | $248.2M | $80.5M | ||
| Q3 25 | $274.6M | $24.8M | ||
| Q2 25 | $294.0M | $10.5M | ||
| Q1 25 | $242.7M | $-27.4M | ||
| Q4 24 | $216.1M | $-35.5M | ||
| Q3 24 | $232.8M | $-9.0M | ||
| Q2 24 | $203.3M | $-34.0M |
| Q1 26 | — | 35.6% | ||
| Q4 25 | 60.3% | 43.5% | ||
| Q3 25 | 61.8% | 43.4% | ||
| Q2 25 | 62.6% | 44.8% | ||
| Q1 25 | 62.4% | 43.6% | ||
| Q4 24 | 59.8% | 42.7% | ||
| Q3 24 | 61.1% | 45.2% | ||
| Q2 24 | 61.7% | 43.9% |
| Q1 26 | — | 59.7% | ||
| Q4 25 | 28.9% | 4.7% | ||
| Q3 25 | 32.1% | 0.8% | ||
| Q2 25 | 33.6% | -2.1% | ||
| Q1 25 | 31.7% | -5.7% | ||
| Q4 24 | 27.4% | -3.3% | ||
| Q3 24 | 31.2% | -3.4% | ||
| Q2 24 | 26.3% | -7.4% |
| Q1 26 | — | -2.2% | ||
| Q4 25 | 22.8% | 5.8% | ||
| Q3 25 | 24.8% | 2.0% | ||
| Q2 25 | 26.5% | 0.9% | ||
| Q1 25 | 24.3% | -2.7% | ||
| Q4 24 | 22.7% | -3.0% | ||
| Q3 24 | 23.9% | -0.9% | ||
| Q2 24 | 20.3% | -3.5% |
| Q1 26 | — | $0.57 | ||
| Q4 25 | $3.09 | $0.55 | ||
| Q3 25 | $3.40 | $0.16 | ||
| Q2 25 | $3.63 | $0.07 | ||
| Q1 25 | $2.96 | $-0.19 | ||
| Q4 24 | $2.62 | $-0.24 | ||
| Q3 24 | $2.80 | $-0.06 | ||
| Q2 24 | $2.44 | $-0.24 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | ||
|---|---|---|
| 現金・短期投資手元流動性 | $180.1M | $2.4B |
| 総負債低いほど良い | $450.0M | — |
| 株主資本純資産 | $1.6B | $2.7B |
| 総資産 | $3.4B | $4.4B |
| 負債/資本比率低いほどレバレッジが低い | 0.28× | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $2.4B | ||
| Q4 25 | $180.1M | $2.3B | ||
| Q3 25 | $208.2M | $2.3B | ||
| Q2 25 | $164.6M | $2.3B | ||
| Q1 25 | $164.0M | $2.3B | ||
| Q4 24 | $288.3M | $2.2B | ||
| Q3 24 | $308.6M | $2.1B | ||
| Q2 24 | $401.6M | $2.1B |
| Q1 26 | — | — | ||
| Q4 25 | $450.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $617.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $2.7B | ||
| Q4 25 | $1.6B | $2.7B | ||
| Q3 25 | $1.6B | $2.6B | ||
| Q2 25 | $1.5B | $2.6B | ||
| Q1 25 | $1.4B | $2.5B | ||
| Q4 24 | $1.6B | $2.5B | ||
| Q3 24 | $1.6B | $2.5B | ||
| Q2 24 | $1.6B | $2.4B |
| Q1 26 | — | $4.4B | ||
| Q4 25 | $3.4B | $4.4B | ||
| Q3 25 | $3.4B | $4.4B | ||
| Q2 25 | $3.3B | $4.3B | ||
| Q1 25 | $3.2B | $4.2B | ||
| Q4 24 | $3.3B | $4.3B | ||
| Q3 24 | $3.4B | $4.3B | ||
| Q2 24 | $3.4B | $4.1B |
| Q1 26 | — | — | ||
| Q4 25 | 0.28× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.39× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | ||
|---|---|---|
| 営業キャッシュフロー直近四半期 | $355.8M | $199.1M |
| フリーキャッシュフロー営業CF - 設備投資 | $326.3M | $298.4M |
| FCFマージンFCF / 売上 | 29.9% | 23.9% |
| 設備投資強度設備投資 / 売上 | 2.7% | — |
| キャッシュ転換率営業CF / 純利益 | 1.43× | — |
| 直近12ヶ月FCF直近4四半期 | $1.1B | $640.0M |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $199.1M | ||
| Q4 25 | $355.8M | $107.7M | ||
| Q3 25 | $402.3M | $127.6M | ||
| Q2 25 | $185.7M | $109.7M | ||
| Q1 25 | $238.0M | $138.7M | ||
| Q4 24 | $262.0M | $79.3M | ||
| Q3 24 | $220.1M | $68.7M | ||
| Q2 24 | $248.3M | $23.4M |
| Q1 26 | — | $298.4M | ||
| Q4 25 | $326.3M | $106.6M | ||
| Q3 25 | $371.2M | $126.5M | ||
| Q2 25 | $151.6M | $108.6M | ||
| Q1 25 | $207.9M | $136.8M | ||
| Q4 24 | $232.8M | $76.8M | ||
| Q3 24 | $192.0M | $67.6M | ||
| Q2 24 | $215.0M | $22.5M |
| Q1 26 | — | 23.9% | ||
| Q4 25 | 29.9% | 7.6% | ||
| Q3 25 | 33.6% | 10.4% | ||
| Q2 25 | 13.7% | 9.8% | ||
| Q1 25 | 20.8% | 13.4% | ||
| Q4 24 | 24.4% | 6.4% | ||
| Q3 24 | 19.7% | 6.4% | ||
| Q2 24 | 21.4% | 2.3% |
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | 0.1% | ||
| Q3 25 | 2.8% | 0.1% | ||
| Q2 25 | 3.1% | 0.1% | ||
| Q1 25 | 3.0% | 0.2% | ||
| Q4 24 | 3.1% | 0.2% | ||
| Q3 24 | 2.9% | 0.1% | ||
| Q2 24 | 3.3% | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | 1.43× | 1.34× | ||
| Q3 25 | 1.47× | 5.14× | ||
| Q2 25 | 0.63× | 10.45× | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 1.21× | — | ||
| Q3 24 | 0.95× | — | ||
| Q2 24 | 1.22× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
IDXX
| Vet Lab Consumables | $389.0M | 36% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32% |
| Rapid Assay Products | $76.0M | 7% |
| Recurring Revenue | $70.6M | 6% |
| CAG Diagnostic Capital Instruments | $58.1M | 5% |
| Water Segment | $50.5M | 5% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3% |
| CAG Diagnostics Service And Accessories | $35.3M | 3% |
| Systems And Hardware | $20.1M | 2% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0% |
ROKU
| Advertising | $612.7M | 49% |
| Subscriptions | $518.5M | 42% |
| Devices | $117.6M | 9% |